Wedbush Reiterates Outperform Rating for SpringWorks Therapeutics (NASDAQ:SWTX)
Wedbush restated their outperform rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report issued on Thursday,RTT News reports. They currently have a $77.00 price target on the stock. Several other research analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $76.00 target price […]
AvidXchange (NASDAQ:AVDX) Stock Price Expected to Rise, Keefe, Bruyette & Woods Analyst Says
AvidXchange (NASDAQ:AVDX – Free Report) had its target price hoisted by Keefe, Bruyette & Woods from $9.00 to $10.00 in a research report released on Thursday,Benzinga reports. They currently have a market perform rating on the stock. A number of other research firms have also recently weighed in on AVDX. The Goldman Sachs Group lowered […]
Monte Rosa Therapeutics (NASDAQ:GLUE) Given “Outperform” Rating at Wedbush
Wedbush reaffirmed their outperform rating on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) in a report issued on Thursday,RTT News reports. The brokerage currently has a $15.00 target price on the stock. Separately, Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $18.00 to $17.00 and set […]
LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a research note published on Thursday,Benzinga reports. The brokerage currently has a $38.00 price target on the stock. Other equities analysts also recently issued reports about the company. Raymond James began coverage on LENZ Therapeutics in a report on […]
KBR (NYSE:KBR) Reaches New 12-Month High – Time to Buy?
KBR, Inc. (NYSE:KBR – Get Free Report) shares reached a new 52-week high on Wednesday . The company traded as high as $71.53 and last traded at $70.90, with a volume of 16258 shares trading hands. The stock had previously closed at $68.03. Wall Street Analyst Weigh In Several equities research analysts have recently issued […]
CSG Systems International (NASDAQ:CSGS) Stock Rating Lowered by StockNews.com
CSG Systems International (NASDAQ:CSGS – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. Several other equities research analysts have also commented on CSGS. Wells Fargo & Company upped their price target on CSG Systems International from $43.00 […]
SpringWorks Therapeutics (NASDAQ:SWTX) Given Outperform Rating at Wedbush
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a report released on Thursday,RTT News reports. They presently have a $77.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 132.70% from the company’s current price. Several other analysts […]
ACADIA Pharmaceuticals’ (ACAD) “Buy” Rating Reaffirmed at HC Wainwright
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $27.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 70.99% from the stock’s current price. Several […]
Cytokinetics (NASDAQ:CYTK) Receives “Buy” Rating from HC Wainwright
Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $120.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 112.80% from the stock’s current price. Several […]
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target upped by equities researchers at JPMorgan Chase & Co. from $100.00 to $105.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of […]
last updated on 9 Nov 01:53